

**RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 20.04.2021)**

Milan, 29<sup>th</sup> March 2021 – Please be informed that the **Annual Financial Report as at 31 December 2020** (including the draft of Statutory Annual Accounts and Consolidated Financial Statements as at 31 December 2020 with the related Directors' Management Report and the required Statements) and the **2020 Consolidated Non-Financial Statements**, both accompanied by the Reports issued by the Independent Auditors, as well as the Report issued by the Board of Statutory Auditors are available to the public, as of today, at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it), Investors - Shareholders' Meeting section) and on the '1INFO' storage mechanism ([www.1info.it](http://www.1info.it)).

The Directors' Report relating to item no. 1 (*financial statement's approval and allocation of profit*) of the agenda of the Ordinary Shareholders' Meeting called for 20<sup>th</sup> April 2021 is available to the public in the same modalities.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations

Studio Noris Morano

(39) 02 76004736, (39) 02 76004745

e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office

Via Matteo Civitali, 1

20148 Milano, Italy

Ph. (39) 02 487871

Fax (39) 02 40073747

[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Tax Code/VAT No. 00748210150

Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l